NO20050838L - Nye pyrazolforbindelser som transformerende vekstfaktor (TGF)-inhibitorer - Google Patents

Nye pyrazolforbindelser som transformerende vekstfaktor (TGF)-inhibitorer

Info

Publication number
NO20050838L
NO20050838L NO20050838A NO20050838A NO20050838L NO 20050838 L NO20050838 L NO 20050838L NO 20050838 A NO20050838 A NO 20050838A NO 20050838 A NO20050838 A NO 20050838A NO 20050838 L NO20050838 L NO 20050838L
Authority
NO
Norway
Prior art keywords
tgf
growth factor
transforming growth
inhibitors
pyrazole compounds
Prior art date
Application number
NO20050838A
Other languages
English (en)
Norwegian (no)
Inventor
Michael John Munchhof
Laura Cook Blumberg
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20050838L publication Critical patent/NO20050838L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20050838A 2002-09-18 2005-02-16 Nye pyrazolforbindelser som transformerende vekstfaktor (TGF)-inhibitorer NO20050838L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41214602P 2002-09-18 2002-09-18
US48454303P 2003-07-02 2003-07-02
PCT/IB2003/003933 WO2004026306A2 (en) 2002-09-18 2003-09-08 Pyrazole derivatives as transforming growth factor (tgf) inhibitors

Publications (1)

Publication Number Publication Date
NO20050838L true NO20050838L (no) 2005-05-18

Family

ID=32033585

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050838A NO20050838L (no) 2002-09-18 2005-02-16 Nye pyrazolforbindelser som transformerende vekstfaktor (TGF)-inhibitorer

Country Status (27)

Country Link
US (4) US6958354B2 (es)
EP (2) EP2165708A3 (es)
JP (1) JP4519657B2 (es)
KR (1) KR20050044807A (es)
CN (1) CN1681501A (es)
AP (1) AP2005003263A0 (es)
AR (1) AR041272A1 (es)
AT (1) ATE450258T1 (es)
AU (1) AU2003259475A1 (es)
BR (1) BR0314302A (es)
CA (1) CA2496295C (es)
CO (1) CO5550456A2 (es)
DE (1) DE60330362D1 (es)
EA (1) EA200500377A1 (es)
EC (1) ECSP055679A (es)
ES (1) ES2335099T3 (es)
HR (1) HRP20050247A2 (es)
IS (1) IS7698A (es)
MA (1) MA27440A1 (es)
MX (1) MXPA05002376A (es)
NO (1) NO20050838L (es)
OA (1) OA12929A (es)
PA (1) PA8583201A1 (es)
PE (1) PE20040988A1 (es)
PL (1) PL375979A1 (es)
UY (1) UY27985A1 (es)
WO (1) WO2004026306A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2005003261A0 (en) 2002-09-18 2005-03-31 Pfizer Prod Inc Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors.
AP2005003264A0 (en) 2002-09-18 2005-03-31 Pfizer Prod Inc Novel imidazole compounds as transforming growth factor (TGD) inhibitors.
PL375979A1 (en) * 2002-09-18 2005-12-12 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
GB0313915D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds
CA2578628A1 (en) * 2004-08-31 2006-03-09 Biogen Idec Ma Inc. Pyrimidinylpyrazoles as tgf-beta inhibitors
WO2006028029A1 (ja) * 2004-09-07 2006-03-16 Sankyo Company, Limited 置換ビフェニル誘導体
CA2584248A1 (en) * 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
CA2629432A1 (en) * 2005-12-16 2007-06-21 Alcon, Inc. Control of intraocular pressure using alk5 modulation agents
PT2089367E (pt) 2006-10-31 2012-02-01 Pfizer Prod Inc Compostos de pirazolina como antagonistas dos receptores mineralcorticóides
AU2008281543A1 (en) * 2007-08-01 2009-02-05 Pfizer Inc. Pyrazole compounds and their use as Raf inhibitors
ES2813875T3 (es) 2014-01-01 2021-03-25 Medivation Tech Llc Compuestos y procedimientos de uso
WO2016160881A1 (en) 2015-04-01 2016-10-06 Rigel Pharmaceuticals, Inc. TGF-β INHIBITORS
WO2016210292A1 (en) 2015-06-25 2016-12-29 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
AU2017235461B2 (en) 2016-03-15 2023-02-23 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
EP3470409B1 (en) * 2016-06-13 2020-02-12 Genfleet Therapeutics (Shanghai) Inc. Benzotriazole-derived alpha and beta-unsaturated amide compound used as tgf-beta ri inhibitor
EP3532604A4 (en) * 2016-10-26 2020-06-03 Icahn School of Medicine at Mount Sinai METHOD FOR INCREASING CELL PROLIFERATION IN PANCREATIC BETA CELLS, TREATMENT METHOD AND COMPOSITION
BR112019008516A2 (pt) 2016-11-14 2019-07-09 Jiangsu Hengrui Medicine Co derivado de 3,4-bipiridil pirazol, e método de preparação para o mesmo e aplicação médica do mesmo
US11547712B2 (en) 2017-11-20 2023-01-10 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
RU2750702C1 (ru) * 2017-12-13 2021-07-01 Джинфлит Терапьютикс (Шанхай) Инк. КРИСТАЛЛИЧЕСКАЯ ФОРМА И СОЛЕВАЯ ФОРМА ИНГИБИТОРА TGF-βRI И СПОСОБ ИХ ПОЛУЧЕНИЯ
US11788064B2 (en) 2018-01-05 2023-10-17 Icahn School Of Medicine At Mount Sinai Method of increasing proliferation of pancreatic beta cells, treatment method, and composition
CA3093340A1 (en) 2018-03-20 2019-09-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
TW202012390A (zh) * 2018-06-29 2020-04-01 日商日本歐愛特農業科技股份有限公司 新穎之經取代吡唑衍生物
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
TW202039459A (zh) 2018-12-11 2020-11-01 美商施萬生物製藥研發 Ip有限責任公司 Alk5 抑制劑
CN110467601B (zh) * 2019-08-29 2021-07-02 杭州市西溪医院 一种吡唑联吡啶酮类化合物、中间体及其制备方法及应用
US11590116B2 (en) 2019-11-22 2023-02-28 Theravance Biopharma R&D Ip, Llc Substituted pyridines and methods of use

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (es) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4925857A (en) * 1989-03-22 1990-05-15 Sterling Drug Inc. Pyridinyl-1H-pyrazole-1-alkanamides as antiarrhythmic agents
JP3734180B2 (ja) * 1994-12-28 2006-01-11 エーザイ株式会社 新規ピラゾール誘導体
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6087381A (en) 1997-05-22 2000-07-11 G. D. Searle & Company Pyrazole derivatives as p38 kinase inhibitors
US5932576A (en) 1997-05-22 1999-08-03 G. D. Searle & Company 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
JP2002541253A (ja) 1999-04-09 2002-12-03 スミスクライン・ビーチャム・コーポレイション トリアリールイミダゾール
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
EP1349851A4 (en) 2000-11-16 2004-09-08 Smithkline Beecham Corp COMPOUNDS
GB0027987D0 (en) 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
GB0100762D0 (en) 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
ES2237671T3 (es) * 2001-02-02 2005-08-01 Smithkline Beecham Corporation Derivados de pirazol contra la sobreexpresion de tgf.
JP2004521901A (ja) * 2001-02-02 2004-07-22 グラクソ　グループ　リミテッド Ｔｇｆ阻害剤としてのピラゾール
GB0102672D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
AP2002002460A0 (en) 2001-03-09 2002-06-30 Pfizer Prod Inc Novel benzimidazole anti-inflammatory compounds.
ATE402164T1 (de) 2001-04-26 2008-08-15 Eisai R&D Man Co Ltd Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
AR040726A1 (es) 2002-07-31 2005-04-20 Smithkline Beecham Corp Compuesto de 2- fenilpiridin-4-il-heterociclico, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento
AP2005003264A0 (en) 2002-09-18 2005-03-31 Pfizer Prod Inc Novel imidazole compounds as transforming growth factor (TGD) inhibitors.
AP2005003261A0 (en) 2002-09-18 2005-03-31 Pfizer Prod Inc Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors.
PL375979A1 (en) 2002-09-18 2005-12-12 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
CA2497971A1 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Triazole derivatives as transforming growth factor (tgf) inhibitors
EA200500286A1 (ru) 2002-09-18 2005-08-25 Пфайзер Продактс Инк. Новые изотиазольные и изоксазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр)
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)

Also Published As

Publication number Publication date
CA2496295C (en) 2010-11-23
PE20040988A1 (es) 2004-12-25
US20100056571A1 (en) 2010-03-04
AU2003259475A1 (en) 2004-04-08
CA2496295A1 (en) 2004-04-01
PL375979A1 (en) 2005-12-12
AP2005003263A0 (en) 2005-03-31
ATE450258T1 (de) 2009-12-15
IS7698A (is) 2005-02-17
CN1681501A (zh) 2005-10-12
OA12929A (en) 2006-10-13
UY27985A1 (es) 2004-04-30
US20060025451A1 (en) 2006-02-02
EA200500377A1 (ru) 2005-08-25
WO2004026306A2 (en) 2004-04-01
PA8583201A1 (es) 2004-04-23
MA27440A1 (fr) 2005-07-01
CO5550456A2 (es) 2005-08-31
ECSP055679A (es) 2005-05-30
EP2165708A2 (en) 2010-03-24
US20070117850A1 (en) 2007-05-24
EP2165708A3 (en) 2010-07-28
WO2004026306A3 (en) 2004-07-01
JP2006507353A (ja) 2006-03-02
US7151110B2 (en) 2006-12-19
AR041272A1 (es) 2005-05-11
US7638537B2 (en) 2009-12-29
ES2335099T3 (es) 2010-03-22
US6958354B2 (en) 2005-10-25
JP4519657B2 (ja) 2010-08-04
BR0314302A (pt) 2005-07-05
EP1542684B1 (en) 2009-12-02
KR20050044807A (ko) 2005-05-12
MXPA05002376A (es) 2005-05-23
DE60330362D1 (de) 2010-01-14
HRP20050247A2 (en) 2005-10-31
US20040116474A1 (en) 2004-06-17
EP1542684A2 (en) 2005-06-22

Similar Documents

Publication Publication Date Title
NO20050838L (no) Nye pyrazolforbindelser som transformerende vekstfaktor (TGF)-inhibitorer
NO20051010L (no) Triazolderivater som transformerende vekst faktor (TGF) inhibitorer
NO20051838L (no) Nye triazol- og oksazolforbindelser som transformerende vekstfaktor (TGF) inhibitor.
NO20051008L (no) Nye imidazolforbindelser som transformerende vekst faktor (TGF) inhibitorer
BRPI0408251A (pt) compostos de pirazina como inibidores do fator de crescimento transformante (tgf)
CA2517933A1 (en) Novel fused heteroaromatic compounds as transforming growth factor (tgf) inhibitors
NO20051852L (no) Nye isotiazol- og isoksazolforbindelser samt transformerende vekstfaktor (TGF)-inhibitorer.
DE69521424T2 (de) Benzofuran derivate und ihre verwendung als inhibitoren der knochenresorption
GB0112348D0 (en) Compounds
SE0103836D0 (sv) Novel compounds
DE60034240D1 (de) Drogen zur behandlung maligner tumoren
DE60205455T2 (de) Naphthyridinderivate
CA2238875A1 (en) Tri-aryl ethane derivatives as pde iv inhibitors
MY133512A (en) Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors
CY1106711T1 (el) Υποκατεστημενα παραγωγα προπανο-1,3-διαμινης και η φαρμακευτικη χρηση τους
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
PE20030236A1 (es) Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados
EE05329B1 (et) GlyT-1 inhibiitorid, neid sisaldavad kompositsioonid, nende kasutamine ja nende valmistamise vahehendid
DE60023154D1 (de) Alkoxy-substituierte benzimidazolverbindungen , diese enthaltende arzneimittel und ihre verwendung
DOP2003000712A (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
CR7747A (es) Nuevos compuestos derivados de isoxazol como inhibidores del factor de crecimiento transformador (tgf)
CR7749A (es) Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf)
ECSP055682A (es) Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf)
DOP2003000719A (es) Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf)